Allogeneic HSCT offers a route for achieving immune tolerance via mixed chimerism and remains the sole curative option for many nonmalignant, autoimmune and metabolic diseases. Present-day improvements of nonmyeloablative protocols are increasing the safety of HSCT, thereby widening the target population and resurrecting the interest of HSCT application as a platform for tolerance induction in organ transplantation. Using high cell doses of T-cell-depleted (TCD) grafts has been shown to circumvent graft-vs-host disease, leaving graft rejection as the main hindrance due to the robust host immunity that remains after mild conditioning. In this review we highlight the advantages of utilizing unique non-alloreactive 'veto' cells, such as anti-third party central memory CD8 T cells (Tcm), to enable induction of mixed chimerism after megadose HSCT under nonmyeloablative conditioning. Co-administration of HSCT with veto Tcm allows for induction of mixed chimerism that was successfully translated into immune tolerance, as demonstrated by engraftment of donor-type skin grafts. These veto Tcm cells have been shown to specifically eradicate anti-donor host T cells, through lymph-node sequestration and deletion, thus sparing host immunity and circumventing the need for life-long immunosuppression. Hence, data indicate that this treatment modality of combined TCD HSCT and adoptive transfer of Tcm veto cells under nonmyeloablative conditions may serve as a valuable tool for treatment of patients with a wide array of disorders such as hemoglobinopathies, autoimmune diseases and as a prelude for organ tolerance.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) offers a curative procedure for patients with malignant and nonmalignant hematological diseases, as well as an expanding number of inherited disorders. To date, one of the most pressing problems in the clinic is the scarcity of HLA-matched donors. Although HLA identical siblings are the ideal source of hematopoietic stem cells (HSC), only 25% of patients have such donors. Therefore, an alternative HSC source is needed for the majority of patients. Alternative options include matched-unrelated donors, unrelated donor umbilical cord blood and full haplotype-mismatched related donor.
Despite the great development of the world registry network of HLA-typed volunteer donors, the application of transplantation using unrelated adult volunteers is still limited by some obstacles; (1) The probability of finding a matched-unrelated donor varies with patients' race, from~70-90% for Caucasians to under 10-50% for ethnic minorities. [1] [2] [3] [4] ( 2) The lengthy process of identifying, typing and harvesting an unrelated donor, with a median time interval between initiation of a search and the donation of marrow of up to 3.5 months, 4, 5 which is impracticable for patients in urgent need of transplantation. Hence, transplantation of mismatched HSC as an alternative source is attractive due to its accessibility and its advantage of conferring graft-versusleukemia activity.
The use of unrelated donor umbilical cord blood has become widespread over the last decade, enjoying the advantages of easy obtainability, the absence of risk for the donor and less stringent criteria for HLA matching for donor-recipient selection.
Yet, impediments for this system are the low engraftment rates, delayed immune reconstitution and raised levels of graft-versus-host disease (GVHD) leading to increases in transplant-related mortality, particularly in adult patients receiving myeloablative preparative regimens. rejection was later found to be mediated by recipient anti-donor cytotoxic T lymphocyte precursors (CTLp) that survive the conditioning regimen. 14, 15 The clinical breakthrough that allowed haploidentical transplantation for acute leukemia patients for the first time was the application of a megadose of TCD hematopoietic progenitor cells. This concept, of escalating stem cell doses to overcome rejection, was first successfully demonstrated in animal models in the early 90's. [16] [17] [18] [19] In humans, escalation of the stem cell dose was afforded by the advent of granulocyte-colony stimulating factor (G-CSF) for donor CD34 + cell mobilization from the bone marrow (BM). 20 Thus, the goal of stem cell escalation was achieved in humans by supplementing the conventional T-cell-depleted bone marrow transplantation (TDBMT) with purified progenitors collected from the blood after administration of G-CSF to the donor. Beginning in 1995, T-cell depletion was replaced by positive selection of CD34 + cells using magnetic beads. This methodology was first applied in Perugia, on high-risk leukemia patients and resulted in primary engraftment of the haploidentical megadose transplants with low rates of GVHD in 493% of the patients, in the absence of posttransplantation GVHD prophylaxis. 21 Comparable results were achieved in other centers in both children 22, 23 and adults. 24, 25 HOW MEGADOSE TRANSPLANTS OVERCOME THE HLA BARRIER The impact of cell dose escalation on the engraftment of TCD-mismatched transplants in both humans and mice, hinted to an immunoregulatory capacity of CD34 + stem cells. This was confirmed by the discovery that CD34 + cells are endowed with 'veto activity'. 26, 27 The veto effect was first described in 1980 by Miller 28 as the ability to specifically suppress CTLp, directed against antigens (Ags) on the veto cells themselves, but not against third-party Ags. 29 Hence, the veto activity is both Ag-specific and MHC restricted, and results from the unidirectional recognition of the veto cell by the responding T cell, but not vice versa. Thus, the recognizing CTLp binds via its T-cell receptor (TCR), which is directed against the MHC of the veto cell, but instead of becoming activated, is killed on binding to its veto target due to exchange of signals allowed following this interaction. This activity is not linked to any single-cell phenotype, but is rather a functional hallmark of a cell; therefore, veto activity has been attributed to various cell types including T lymphocytes, natural killer cells and dendritic cells.
This specificity of veto cells can be harnessed as an effective modality for the induction of donor-specific immune tolerance in transplantation settings where the addition of donor veto cells, adept in eliminating solely the host anti-donor T-cell clones that mediate the transplant rejection, spares all additional T cells that can persist and fight infectious pathogens. The finding that CD34 + stem cells were equipped with veto capability, via TNF-α-mediated deletion, 26, 30 was soon followed by the discovery that early myeloid CD33 + cells, which rapidly expand after engraftment, are also endowed with marked veto activity, which is absent from late myeloid cells that express CD14 or CD11b. 27, 30 BM-derived immature dendritic cells, formerly described as competent inducers of immune tolerance, were also found to possess veto activity directed against CD8 T cells using a distinct MHCdependent, perforin-based killing mechanism involving activation of Toll-like receptor 7 and signaling through triggering receptor-1 expressed on myeloid cells. 31, 32 Natural killer cells, also found to exhibit veto activity on activation with IL-2, develop and appear early during the post-transplant period. 33, 34 Hence, the ability of CD34 + cell megadose to overcome antidonor activity probably occurs in steps; first the host anti-donor CTLp are dwindled by the veto exerted by the infused CD34 + cells, this activity is then reinforced by the CD33 + progeny expansion and finally the tolerance is maintained by BM-derived CD11c + immature DCs and natural killer cells, which come into play after donor BM has seeded.
MEGADOSE OF TCD HSCT UNDER REDUCED-INTENSITY CONDITIONING
Although the number of mismatched allogeneic transplants has increased steadily over the past few decades, TCD HSCT remains a high-risk procedure on account of conditioning-related toxicities and slow immune reconstitution, and is therefore reserved for patients with life-threatening diseases. To this end, reduced-intensity (RIC)/nonmyeloablative-conditioning regimens are continuously being perfected, expanding the range of patients who can benefit from the procedure (that is, elderly patients, patients with comorbidities and patients with nonmalignant disorders). Not only do these regimens reduce transplant-related mortality, they also promote mixed, rather than full, donor chimerism, a state in which the lymphohematopoietic system of the recipient of allogeneic HSC consists of a mixture of host and donor cells. This state of mixed chimerism, has largely been associated with improved immunity and central tolerance. [35] [36] [37] [38] [39] The major advantage of RIC is also its main caveat, while sparing much of the host immunity improves immune reconstitution; it also allows a robust host-versus-graft response, which increases the chances of graft rejection.
The ability of HSCT megadose to induce mixed chimerism under RIC was first demonstrated in sublethally (7 Gy) irradiated mice in 1999. This mixed chimerism induced specific tolerance to donortype skin grafts was facilitated by BM cells within the Sca-1 + Lin + cell fraction capable of specifically deleting anti-donor CTLp both in vitro and in vivo. 17, 40 However, the high numbers of CD34 + cells required to overcome graft rejection under RIC conditions suitable for elderly or nonmalignant patients cannot presently be attained with state of the art technologies (Gan et al., unpublished results). One approach to overcome this hurdle was to seek alternative immunoregulatory cells, such as other types of veto cells, that could be adoptively transferred with the allogeneic TCD megadose graft to allow its application under RIC.
COMBINING MISMATCHED TCD MEGADOSE BM WITH ADOPTIVE TRANSFER OF VETO CELLS UNDER RIC
Of the various types of veto cells described over the years, none are more potent than CD8 + cytotoxic T-cell (CTL) lines or clones. 34, [41] [42] [43] [44] To eliminate the innate ability of such cells to instigate graft versus host immunity in allogeneic settings, we developed a new approach for the generation of host-nonreactive CTLs, by stimulation of donor CD8 + T cells against thirdparty stimulators under cytokine deprivation, followed by further ex vivo expansion using third-party stimulators and IL-2. This approach was based on the observation that only activated CTLs are capable of surviving the cytokine deprivation in the primary culture due to their autocrine secretion of cytokines upon activation. Hence, surviving cells are anti-third-party specific clones (that is, CTLp that carry a TCR-specific for MHC + peptide on the third party stimulator cells), which can then be expanded by addition of IL-2 to the culture. 45 Anti-third-party CTLs were found to exhibit potent veto activity in vitro 34, 46 and could support engraftment of fully mismatched TDBM allograft in murine models in an MHC-specific manner, without initiating GVHD. 45 Similar results were shown when using F1-derived anti-third party CTLs, inherently incapable of exerting alloreactive responses, further demonstrating that this response is TCR independent. 45, 47 Induction of engraftment was shown to be the result of anti-third-party veto CTL-mediated elimination of both naive and memory host anti-donor cells, 48 significant for clinical translation as T-memory cells are known to obstruct tolerance induction in humans. [48] [49] [50] [51] [52] [53] [54] Interrogation of the veto CTL mechanism has shown that co-expression of CD8 and FAS ligand is required for the veto activity of these cells. 34, 46 In this process, the CTLp binds in a TCR-specific manner to the veto cell, which then leads to the elevation of FAS expression on the now activated CTLp. Subsequently, inhibitory molecules (for example, FLICE-inhibitory protein) are downregulated in the CTLp, thereby enabling FAS-FAS ligand-mediated apoptosis. Veto CD8-effector MHC class I α3 domain interactions are also essential to the process, for promoting cell-contact stability, but more significantly for triggering the phosphorylation of MEK/ERK in CTLp ensuing reduction of the X-linked inhibitor of apoptosis protein levels, which, in turn, increases the potency of the FAS-FAS ligandmediated apoptosis. 55 More recently, and in addition to their ability to mediate veto via FAS ligand, anti-third-party CTLs were also shown to utilize a perforin mediated mechanism, that manifests prior to the upregulation of FAS on the CTLp. 56 Interestingly, the in vivo activity of anti-third party CTLs was inferior to their in vitro activity, demanding administration of large number of CTLs in conjunction with the immunosuppressive drug rapamycin. 45 This reduced in vivo responsiveness stemmed from the lack of ability of veto CTLs, which are effector cells that home to the periphery, to co-localize with host anti-donor CTLp in the lymph nodes (LNs), before the latter differentiate into effector cells, become unsusceptible to the veto effect and instigate graftversus-host response. 57 This was nicely demonstrated by comparing the migration patterns of anti-third-party CTLs to that of naive host T cells, which showed that unlike naive host T cells that home efficiently to the LNs of BMT-recipient mice, veto CTLs are excluded from the LNs and tend to localize to peripheral sites. 58 To accommodate the need for veto cell LNs homing, a new type of host non-reactive veto cell with a central memory-like phenotype was successfully tested for induction of tolerance and engraftment of TDBMT. 58 This was done by culturing activated CD8 + T cells, after cytokine deprivation, with interleukin-15, known to push cells to acquire a central memory-like phenotype. [59] [60] [61] Central memory T cells (Tcm) are known to express the LN-homing receptors CD62L and CCR7 62 and, like naive T cells, localize to T-cell areas of all secondary lymphoid organs. 63 Consistent with their memory state, Tcm respond faster and more vigorously than naive T cells when re-encountering cognate Ag, [60] [61] [62] [63] [64] and therefore possess a heightened capacity to confer host protection against pathogens and tumors. 59, 64, 65 Like 'natural' Tcm, in vitro-generated Tcm-like cells are incapable of immediate cytotoxicity and display the typical Tcm migratory pattern. 63 Indeed, ex vivo-induced anti-third-party Tcm, in contrast to anti-third-party CTLs, were shown to home to LNs of TDBMT recipients, where they colocalized with and subsequently eradicated host anti-donor CTLp, thereby overcoming graft rejection. In line with their memory phenotype, anti-third-party Tcm greatly proliferated in the early post-transplant period and persisted in vivo for well over a year post BMT. 58 Anti-third-party Tcm derived from F1 mice were shown to specifically and efficiently delete host TCR-transgenic T cells carrying a TCR transgene with anti-donor specificity via apoptosis. This specific deletion of host anti-donor cells resulted in TDBMT allograft engraftment with mixed donor chimerism in the absence of GVHD (Figure 1b) , in both lethally and reduced conditioned mice. 66 Importantly, this chimerism resulted in successful donor skin acceptance, whereas third-party skin was rejected (Figure 1c) . 66 Tracking host anti-donor CTLp, which mediate TDBMT rejection, in a novel bioluminescence-imaging model revealed that Tcm induce initial accumulation of CTLp in the LNs, concomitant with their elimination from other organs, including the BM (Figure 1d ). Further analysis using two-photon microcopy revealed that Tcm form conjugates with CTLp (Figure 1e ), resulting in decelerated and confined movement of CTLp within the LNs (Figure 1f ), followed by apoptosis-mediated deletion of these cells in an Agspecific manner (Figure 1g ). Hence, anti-third-party Tcm support TDBMT engraftment under reduced-conditioning through lymphnode sequestration and deletion of host anti-donor CTLp, offering a novel and potentially safe approach for attaining stable hematopoietic chimerism. 66 
POTENTIAL APPLICATION OF MEGADOSE HSCT WITH TCM VETO CELLS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
Allogeneic transplantation remains the sole curative option for hemoglobinopathies such as β-thalassemia and sickle cell anemia (SCA). High cure rates have been noted for pediatric SCA patients undergoing HSCT following myeloablative conditioning protocols, mostly using busulfan and cyclophosphamide for myeloablation, [67] [68] [69] [70] [71] along with cyclosporine and methotrexate as GVHD prophylaxis. Adult SCA and thalassemia patients treated with these protocols suffered from transplant-related toxicity 72, 73 and were therefore excluded from many of these studies.
Only 40% of patients requiring HSCT have a suitable HLA-matched family donor, thus the use of haploidentical HSCT has been explored as an alternative source for patients lacking a matched donor. Sodani et al. 74, 75 describes a trial in pediatric thalassemia patients receiving a haploidentical transplantation of a megadose of purified CD34+ cells and a highly immunomyeloablative-conditioning regimen (hydroxyurea, azathioprine, fludarabine, busulfan or busulfan+cyclophospha-mide, thiotepa and anti-thymocyte globulin) with GVHD prophylaxis for 2 months after transplantation. In this study 22/31 patients were cured, however 7 rejected the graft and 3 died of transplant-related complications. The adverse effects of the high regimen-related toxicity has stopped HSCT from being offered to older hemoglobinopathy patients.
Mixed chimerism after nonmyeloablative HSCT has been found beneficial for both thalassemia and SCA patients, [76] [77] [78] [79] where a limited percentage of engrafted donor cells may be sufficient to overcome disease phenotype. Thus, the rationale for lowerintensity conditioning is relevant, because of its ability to promote mixed tolerance and the decreased risk for transplant-related toxicity and mortality, which will open HSCT-curative treatment to more patients. Attempts to use RIC protocols have mainly focused on HLA-matched HSCT for SCA, producing some favorable [80] [81] [82] and some unfavorable 83, 84 outcomes depending on the regimen used. Results of a phase 1/2 haploidentical HSCT trial on adult SCA patients under RIC (anti-thymocyte globulin, cyclophosphamide, fludarabine, 2 Gy TBI, cyclophosphamide and tacrolimus GVHD prophylaxis) showed that 17/31 patients accepted the graft and 11 of them were disease free. No GVHD was noted 85 but the high rejection rate (43%) warrants further tuning of the preparatory regimen.
Our previous demonstrations that combined TCD HSCT and adoptive transfer of Tcm veto cells under nonmyeloablative conditions facilitates graft acceptance, indicates that this treatment modality could potentially offer an attractive option for patients with hemoglobinopathies, without the risk for GHVD and transplant-related toxicities.
INDUCTION OF TOLERANCE IN ORGAN RECIPIENTS BY COMBINING VETO TCM AND HSCT
Current advances in nonmyeloablative HSCT protocols have rejuvenated the interest in the application of HSCT as a platform for tolerance induction in organ transplantation. This approach aims to utilize HSCT to achieve mixed chimerism, which will then provide the necessary immune tolerance for survival and thriving of the transplanted solid organ. Within this field, the greatest progress has been made in the area of kidney transplantation. 86 In one approach, limited to HLA-matched donors, Scandling et al. has been utilizing TCD HSCT megadose following kidney transplantation, in patients conditioned with post-transplantation TLI and anti-thymocyte globulin. [87] [88] [89] Adaptation to haploidentical donors currently include significantly increased donor T-cell numbers, entailing heightened risk of GVHD. Other protocols have utilized megadose TCD HSCT after a preparative regimen of cyclophosphamide, monoclonal anti-CD2 Ab therapy (MEDI-507; MedImmune) for in vivo TCD, retuximab and thymic irradiation for induction of mixed tolerance. [90] [91] [92] [93] [94] Although 70% of patients displayed donor-specific unresponsiveness, 92, 95 only transient chimerism was achieved, few subjects rejected transplants 95 and 9/10 patients suffered from 'engraftment syndrome' (that is, capillary leak syndrome) 96, 97 associated with increased transplantrelated mortality and production of anti-donor antibodies. Seemingly, the most successful strategy thus far to achieve combined kidney transplants and haploidentical HSCT has been described by Leventhal et al. making use of partially cell-depleted HSCT, enriched with 'facilitating-cells' following nonmyeloablative conditioning (TBI, cyclophosphamide, fludarabine).
98-100 Inclusion of a substantial number of alloreactive T cells (2 × 10 6 /kg) in the graft seems to be critical for engraftment but also entails a risk for GVHD. Thus, the safety of this protocol might be markedly enhanced by replacing the high number of alloreactive donor T cells in the graft with Tcm veto cells, free of GVHD risk.
CONCLUDING REMARKS
Induction of hematopoietic mixed chimerism by means of BMT offers a promising approach by which to achieve immune tolerance. Allogeneic HSCT is the curative option for multiple nonmalignant diseases including immunodeficiency syndromes, 101, 102 autoimmune disease, 103, 104 inherited metabolic disorders 105 and hemoglobinopathies such as thalassemia and SCA. 70, 73 Moreover, allogeneic HSCT can also serve as a platform for the subsequent engraftment of organ transplants without the need for continuous immunosuppressive therapy. The main barriers today remain the transplant-related complications and the lack of HLA-matched donors. The use of non-matched transplants, such as transplants from a haploidentical donor boasts the advantage of high availability. Safe transplantation of haploidentical HSCT has been achieved in T-cell-depleted megadose stem cell transplants under RIC, affording safe induction of stable long-term mixed chimerism, in the absence of GVHD. However, insights gained from the use of megadose stem cell transplants on immune tolerance exhibited by HSCs and their early myeloid derivatives suggest that while these cells can effectively overcome residual host CTLs surviving the myeloablative conditioning in leukemia patients, the same stem cell number is not capable of overcoming the large quantity of T cells remaining after RIC. Hence, the use of different sources of tolerizing cells, devoid of graft versus host reactivity, could facilitate engraftment of hematopoietic allografts under reduced conditioning, without the unwanted complications of GVHDproducing T cells. In particular, host non-reactive anti-third-party Tcm have been shown to be good candidate veto cells, as they facilitate engraftment of fully mismatched TDBM megadose, thereby promoting mixed chimerism and immune tolerance in murine models. If indeed the use of these veto Tcm will translate well into human subjects, demonstrating improved relapse and transplant-related mortality rates, in the absence of GVHD, its application could be further extended to treat diseases that are lethal over the course of years, but that do not present an immediate threat, such as nonmalignant hematological diseases and autoimmune disorders. Furthermore, this modality could be used as a prelude for cell therapy and as a platform for organ transplantation.
